Skip to main navigation Skip to search Skip to main content

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

Research output: Contribution to journal › Article › peer-review

Abstract

The ability of cord blood transplantation (CBT) to prevent relapse depends partly on donor natural killer (NK) cell alloreactivity. NK effector function depends on specific killer-cell immunoglobulin-like receptors (KIR) and HLA interactions. Thus, it is important to identify optimal combinations of KIR-HLA genotypes in donors and recipients that could improve CBT outcome.We studied clinical data, KIRandHLA genotypes, and NK-cell reconstitution inCBTpatients (n5110).Resultswerevalidatedinanindependentcohort (n594).HLA-KIR genotypingof recipientgermlineandtransplantedcordblood(CB)graftspredictedfor large differences in outcome. Patients homozygous for HLA-C2 group alleles had higher 1-year relapse rate and worse survival after CBT than did HLA-C1/C1 or HLA-C1/C2 (HLA-C1/x) patients: 67.8% vs 26.0% and 15.0% vs 52.9%, respectively. This inferior outcome was associated with delayed posttransplant recovery of NK cells expressing the HLA-C2-specific KIR2DL1/S1 receptors. HLA-C1/x patients receiving a CB graft with the combined HLA-C1-KIR2DL2/L3/S2 genotype had lower 1-year relapse rate (6.7% vs 40.1%) and superior survival (74.2% vs 41.3%) compared with recipients of grafts lacking KIR2DS2 or HLA-C1. HLA-C2/C2 patients had lower relapse rate (44.7% vs 93.4%) and better survival (30.1% vs 0%) if they received a graft with the combined HLA-C2-KIR2DL1/S1 genotype. Relapsed/ refractory disease atCBT, recipient HLA-C2/C2 genotype, and donor HLA-KIR genotype were independent predictors of outcome. Thus, wepropose the inclusion of KIRgenotyping in graft selection criteria forCBT. HLA-C1/x patients should receive an HLA-C1-KIR2DL2/L3/ S2 CB graft, while HLA-C2/C2 patients may benefit from an HLA-C2-KIR2DL1/S1 graft.

Original languageEnglish (US)
Pages (from-to)297-312
Number of pages16
JournalBlood
Volume128
Issue number2
DOIs
StatePublished - Jul 14 2016

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

MD Anderson CCSG core facilities

  • Clinical Trials Office

Fingerprint

Dive into the research topics of 'Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation'. Together they form a unique fingerprint.

Cite this